Dopavision

Dopavision is a Berlin-based startup focused on leveraging innovative solutions to tackle unmet needs in ophthalmology using digitally delivered light. Their flagship product, MyopiaX®, targets myopia, a prevalent global public health concern, by stimulating specific photosensitive cells of the retina to modulate retinal dopamine. This intervention is particularly targeted at children and young adolescents to address myopia early and provide long-term medical benefits. Since its founding in 2017, Dopavision GmbH has secured a total of €16.2 million in private equity and public grants, with its latest funding being a €12.00M Series A investment in July 2021. The investors in this round include big names such as Seventure Partners, Novartis Pharma (dRx Capital), Boehringer Ingelheim Venture Fund, and Ababax Health. The company's goal is to continue funding the clinical development of MyopiaX® and ongoing scientific research and product development activities.